rimonabant - Risks too high

Rimonabant (also known as Acomplia) is a drug which is used to treat obese patients with a risk of developing diabetes.

As I blogged about a month or so ago, the drug is considered controversial. There is now evidence to suggest that one in every ten people that take the drug suffer from some kind of psychiatric side-effect.

We say this is too high! Mental health issues are not taken seriously enough, and any drug which has this much potential to cause psychiatric side-effects should be banned (as it is already in the USA).

Treating diabetes and obesity related cardiovascular disease is important, but not at the risk of causing suicidal thoughts, depression, and, in one known case, self-harm.

It is time for some joined up thinking when it comes to medication which effects how our brain functions. The organisations and bodies that licence drugs need to be better prepared to stop harmful drugs reaching patients. This habit of stopping drugs which have now been used , and done harm, for some time has to be replaced by a more efficient system.

Mental health drugs overused

Hi!

This article seems to confirm what a lot of us already know. That doctors in the westernised world are encouraged to overprescribe drugs to patients who actually would do much better with other forms of treatment. Yes drugs are cheap, but they do not get to the heart of the problem, even if they are successful often this is just a crutch.

Although longer term, more labour intensive treatments seem to be more expensive in fact they are not. If you look at the longterm benefits to the whole economy of having a workforce in sound mental health you will find that it is an investment to take mental healthcate seriously.

So let's see better strategies for mental health, depression, anxiety, chronic fatigue and panic attacks.

Here's the article:

Up to one in three mental health patients are being over-prescribed drugs, says the Healthcare Commission.
A report found mental health patients were more likely to have problems with medicines than those in other trusts.

The healthcare watchdog said management of mental healthcare patients' medicines must improve, and pharmacists should be involved in patient care.

It said the findings were "concerning" given the importance of medicines in mental healthcare.

Healthcare Commission Chief Executive Anna Walker said: "Managing medicines safely, effectively and efficiently is central to the delivery of high quality care that is focused on the patient and gives value for money."

She called on both primary care trusts and mental health trusts to look at their medicines management, and said patients in mental health trusts had told the Commission that they had not been involved as much as they would like in decisions about their medicines.

She said: "This needs to be addressed if trusts expect service users to take their medicines as prescribed."

Over-prescription

In research undertaken by the Prescribing Observatory for Mental Health, 36% of people were found to have been prescribed more than the maximum recommended dose of anti-psychotic medicines.

Mental health charity Rethink called for an end to the over-prescription of mental health medicines.

The charity's chief executive Paul Jenkins said: "The Healthcare Commission has once again highlighted a shocking over-prescription of powerful medicines to people in hospital experiencing a mental health crisis.

"As well as defying national guidance, this over-prescription actually delays successful discharge in many cases.

"Everyone has the right to the best evidence-based care, but it is unacceptable that people experiencing a mental health crisis can still be treated as second class citizens."

Reviews helpful

The Commission said the problem could be detected by an effective clinical pharmacy service.

It found that reviewing medication benefited patients, with 70% of reviews in mental health trusts leading to a change in a person's medicine, and 46% of those reviewed being found not to be taking their medicines appropriately.

David Pruce, Director of Practice and Quality Improvement from the Royal Pharmaceutical Society of Great Britain said: "The evidence shows that medication reviews in mental health by specialist pharmacists can have a major impact, with over 70% of the reviews leading to a change in the patient's medication."

Yet 24% of wards in mental health trusts received no visits from pharmacy staff, compared to only 14% in acute trusts, and just 14% received more than five hours of pharmacy staff time in a week, compared to 64% in acute trusts.

Mr Pruce said: "The future should see specialist mental health pharmacists having an increased role in the care of patients."

Not complacent

National Clinical Director for Mental Health, Professor Louis Appleby said: "We recognise that the safe and effective management of medicines is central to the delivery of high quality patient care.

"This report will help services address a very important issue and ensure that patients are fully involved in decisions about - and get the most from - their medicines.

"We are not complacent and more work is needed to ensure that all Trusts reach the standards of the best."


link